Companies Quest Diagnostics Inc
Quest Diagnostics (DGX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Quest Diagnostics Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers36th pct.Of 14 peer CEOs
CEO pay, last three years
- $12,673,834FY2023
- $14,404,862FY2024
- $15,498,479FY2025
CEO total pay was $15,498,479 in fiscal 2025, up from $14,404,862 in fiscal 2024.
FY2025: salary $1,250,000 · bonus $0 · stock awards $8,762,861 · option awards $2,999,873
Executives and directors
James Davis · CEOKarthik Kuppusamy · SVPCatherine Doherty · EVPMichael Prevoznik · General CounselSam Samad · CFODenise M. Morrison · Independent DirectorGary M. Pfeiffer · Independent DirectorLuis A. Diaz, Jr · Independent DirectorRobert B. Carter · Independent DirectorTimothy C. Wentworth · Independent DirectorTimothy L. Main · Independent DirectorTimothy M. Ring · Lead Independent DirectorTracey C. Doi · Independent DirectorVicky B. Gregg · Independent DirectorWright L. Lassiter III · Independent Director
Frequently asked questions
Who was the highest-paid executive at Quest Diagnostics Inc in fiscal 2025?
As disclosed, James Davis (Chairman, Chief Executive Officer and President) was the highest-paid executive at Quest Diagnostics Inc in fiscal 2025, with total compensation of $15,498,479.
How does Quest Diagnostics Inc's chief executive pay compare to its disclosed peer group?
As disclosed, James Davis's total compensation ranked at the 36th percentile of Quest Diagnostics Inc's disclosed peer group.
What is Quest Diagnostics Inc's CEO-to-median employee pay ratio?
As disclosed, Quest Diagnostics Inc's CEO-to-median employee pay ratio was 275:1.
How did shareholders vote on Quest Diagnostics Inc's executive compensation?
As disclosed, 92.39% of shareholders supported Quest Diagnostics Inc's executive compensation in the latest say-on-pay vote.
How much does Quest Diagnostics Inc spend in total on board compensation for fiscal 2025?
As disclosed, Quest Diagnostics Inc reported total board compensation of $3,059,253 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| James Davis | $1,250,000 | $0 | $8,762,861 | $2,999,873 | $2,205,844 | $0 | $279,901 | $15,498,479 |
| Chairman, Chief Executive Officer and President | ||||||||
| Sam Samad | 693,269 | 0 | 2,190,967 | 749,742 | 710,358 | 0 | 82,805 | 4,427,141 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Catherine Doherty | 643,269 | 0 | 1,679,674 | 574,876 | 615,184 | 0 | 49,943 | 3,562,946 |
| Executive Vice President, Regional Businesses | ||||||||
| Karthik Kuppusamy | 568,269 | 0 | 1,095,483 | 374,893 | 475,526 | 0 | 65,652 | 2,579,823 |
| Senior Vice President, Clinical Solutions | ||||||||
| Michael Prevoznik | 550,000 | 0 | 1,132,015 | 387,343 | 438,323 | 0 | 55,912 | 2,563,593 |
| Senior Vice President and General Counsel | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| James Davis | $15,498,479 | $14,404,862 | $12,673,834 | ↑ +1,093,617 |
| Sam Samad | 4,427,141 | 4,068,464 | 3,975,114 | ↑ +358,677 |
| Catherine Doherty | 3,562,946 | 3,286,080 | 3,158,844 | ↑ +276,866 |
| Karthik Kuppusamy | 2,579,823 | 2,277,691 | 2,015,205 | ↑ +302,132 |
| Michael Prevoznik | 2,563,593 | 2,428,646 | 2,251,920 | ↑ +134,947 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Semler Brossy |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Catherine Doherty | RSU | 2025-02-12 | — | — | 3,479 | — | $575,079 |
| Michael Prevoznik | RSU | 2025-02-12 | — | — | 2,345 | — | 387,629 |
| James Davis | RSU | 2025-02-12 | — | — | 18,149 | — | 3,000,030 |
| Karthik Kuppusamy | PSU | 2025-02-12 | 318 | 4,238 | — | 8,476 | 720,418 |
| Michael Prevoznik | PSU | 2025-02-12 | 328 | 4,379 | — | 8,758 | 744,386 |
| Sam Samad | RSU | 2025-02-12 | — | — | 4,538 | — | 750,131 |
| Karthik Kuppusamy | RSU | 2025-02-12 | — | — | 2,269 | — | 375,066 |
| James Davis | PSU | 2025-02-12 | 2,543 | 33,901 | — | 67,802 | 5,762,831 |
| Catherine Doherty | PSU | 2025-02-12 | 487 | 6,498 | — | 12,996 | 1,104,595 |
| Sam Samad | OPTION | 2025-02-12 | — | — | 17,403 | — | 749,742 |
| Karthik Kuppusamy | OPTION | 2025-02-12 | — | — | 8,702 | — | 374,893 |
| Catherine Doherty | OPTION | 2025-02-12 | — | — | 13,344 | — | 574,876 |
| Sam Samad | PSU | 2025-02-12 | 636 | 8,476 | — | 16,952 | 1,440,835 |
| Michael Prevoznik | OPTION | 2025-02-12 | — | — | 8,991 | — | 387,343 |
| James Davis | OPTION | 2025-02-12 | — | — | 69,633 | — | 2,999,873 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Catherine Doherty | $575,079 | $1,104,595 | $574,876 | 49.0% |
| Michael Prevoznik | 387,629 | 744,386 | 387,343 | 49.0% |
| James Davis | 3,000,030 | 5,762,831 | 2,999,873 | 49.0% |
| Karthik Kuppusamy | 375,066 | 720,418 | 374,893 | 49.0% |
| Sam Samad | 750,131 | 1,440,835 | 749,742 | 49.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Karthik Kuppusamy | RSU | 1,761 | — | $305,586 |
| Michael Prevoznik | RSU | 1,957 | — | 339,598 |
| Karthik Kuppusamy | RSU | 2,269 | — | 393,740 |
| Michael Prevoznik | RSU | 2,345 | — | 406,928 |
| Karthik Kuppusamy | Option | 2,757 | 143.33 | — |
| Catherine Doherty | RSU | 2,870 | — | 498,031 |
| Michael Prevoznik | Option | 3,218 | 143.33 | — |
| Catherine Doherty | RSU | 3,479 | — | 603,711 |
| Sam Samad | RSU | 3,652 | — | 633,732 |
| Sam Samad | RSU | 4,538 | — | 787,479 |
| Catherine Doherty | Option | 5,056 | 143.33 | — |
| Sam Samad | Option | 6,206 | 143.33 | — |
| Karthik Kuppusamy | RSU | 6,898 | — | 1,197,010 |
| Karthik Kuppusamy | Option | 7,338 | 127.81 | — |
| Michael Prevoznik | RSU | 8,046 | — | 1,396,222 |
| Michael Prevoznik | Option | 8,154 | 127.81 | — |
| Karthik Kuppusamy | PSU | 8,476 | — | 1,470,840 |
| Karthik Kuppusamy | Option | 8,702 | 165.3 | — |
| Michael Prevoznik | PSU | 8,758 | — | 1,519,776 |
| Michael Prevoznik | Option | 8,991 | 165.3 | — |
| Karthik Kuppusamy | PSU | 10,526 | — | 1,826,577 |
| Michael Prevoznik | PSU | 11,694 | — | 2,029,260 |
| Catherine Doherty | Option | 11,960 | 127.81 | — |
| Catherine Doherty | RSU | 12,644 | — | 2,194,113 |
| Catherine Doherty | PSU | 12,996 | — | 2,255,196 |
| Catherine Doherty | Option | 13,344 | 165.3 | — |
| James Davis | RSU | 14,834 | — | 2,574,144 |
| Sam Samad | Option | 15,224 | 127.81 | — |
| Sam Samad | RSU | 15,517 | — | 2,692,665 |
| Sam Samad | PSU | 16,952 | — | 2,941,681 |
| Catherine Doherty | PSU | 17,152 | — | 2,976,387 |
| Sam Samad | Option | 17,403 | 165.3 | — |
| James Davis | RSU | 18,149 | — | 3,149,396 |
| Sam Samad | PSU | 21,828 | — | 3,787,813 |
| James Davis | Option | 22,986 | 143.33 | — |
| James Davis | RSU | 57,467 | — | 9,972,249 |
| James Davis | Option | 61,853 | 127.81 | — |
| James Davis | PSU | 67,802 | — | 11,765,681 |
| James Davis | Option | 69,633 | 165.3 | — |
| James Davis | PSU | 88,676 | — | 15,387,946 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Timothy M. RingIndependent · Lead Independent Director · Compensation and Leadership Development · Executive (Chair) · Governance (Chair) | $170,000 | $209,917 | $0 | $0 | $0 | $379,917 |
| Gary M. PfeifferIndependent · Audit and Finance (Chair) · Compensation and Leadership Development · Executive · Governance | 140,000 | 209,917 | 0 | 0 | 0 | 349,917 |
| Vicky B. GreggIndependent · Compensation and Leadership Development · Governance · Quality and Compliance (Chair) | 135,000 | 209,917 | 0 | 0 | 0 | 344,917 |
| Denise M. MorrisonIndependent · Compensation and Leadership Development (Chair) · Cybersecurity · Governance | 135,000 | 209,917 | 0 | 0 | 0 | 344,917 |
| Timothy L. MainIndependent · Audit and Finance · Cybersecurity (Chair) · Governance | 130,000 | 209,917 | 0 | 0 | 0 | 339,917 |
| Luis A. Diaz, JrIndependent · Cybersecurity · Quality and Compliance | 115,000 | 209,917 | 0 | 0 | 0 | 324,917 |
| Wright L. Lassiter IIIIndependent · Audit and Finance · Quality and Compliance | 115,000 | 209,917 | 0 | 0 | 0 | 324,917 |
| Tracey C. DoiIndependent · Audit and Finance · Quality and Compliance | 115,000 | 209,917 | 0 | 0 | 0 | 324,917 |
| Robert B. CarterIndependent · Audit and Finance · Cybersecurity | 115,000 | 209,917 | 0 | 0 | 0 | 324,917 |
| Timothy C. WentworthIndependent · Compensation and Leadership Development · Quality and Compliance · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| James E. DavisEmployee director · Board Chair · Executive | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $115,000 |
|---|---|
| Annual equity retainer | $210,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 15,000 |
| Stock ownership guideline | $5 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,170,000 |
| Equity awards (grant-date value) | $1,889,253 |
| All other compensation | $0 |
| Total cost of the board | $3,059,253 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Quest Diagnostics as a peer
Companies that benchmark against DGX
30 companies name DGX as a compensation peer
- ACCENDRA HEALTH INC/VA/ACHFY2025
- agilon health, inc.AGLFY2025
- Alignment Healthcare, Inc.ALHCFY2025
- Ardent Health, Inc.ARDTFY2025
- Astrana Health, Inc.ASTHFY2025
- Avantor, Inc.AVTRFY2025
- BAXTER INTERNATIONAL INCBAXFY2025
- BOSTON SCIENTIFIC CORPBSXFY2025
- BrightSpring Health Services, Inc.BTSGFY2025
- Brookdale Senior Living Inc.BKDFY2025
- Cencora, Inc.CORFY2025
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRLFY2025
- COMMUNITY HEALTH SYSTEMS INCCYHFY2025
- CVS HEALTH CorpCVSFY2025
- DAVITA INC.DVAFY2025
- Encompass Health CorpEHCFY2025
- GE HealthCare Technologies Inc.GEHCFY2025
- HENRY SCHEIN INCHSICFY2025
- LABCORP HOLDINGS INC.LHFY2025
- Medpace Holdings, Inc.MEDPFY2025
- MOLINA HEALTHCARE, INC.MOHFY2025
- Option Care Health, Inc.OPCHFY2025
- PATTERSON COMPANIES, INC.PDCOFY2024
- REVVITY, INC.RVTYFY2025
- STRYKER CORPSYKFY2025
- UNIVERSAL HEALTH SERVICES INCUHSFY2025
- ZIMMER BIOMET HOLDINGS, INC.ZBHFY2025
Each company listed discloses DGX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named DGX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
A Agilent Technologies, Inc.LH Laboratory Corporation of America HoldingsBSX Boston Scientific CorporationDVA DaVita Inc.HSIC Henry Schein, Inc.ILMN Illumina, Inc.BAX Baxter International Inc.BDX Becton, Dickinson and CompanyRVTY Revvity, Inc.SYK Stryker CorporationTHC Tenet Healthcare CorporationHOLX Hologic, Inc.ZBH Zimmer Biomet Holdings, Inc.ACH Owens & Minor, Inc.
Peer reciprocity
Of the companies Quest Diagnostics Inc names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
— Agilent Technologies, Inc. (A)104✓ Laboratory Corporation of America Holdings (LH)105✓ Boston Scientific Corporation (BSX)106✓ DaVita Inc. (DVA)107✓ Henry Schein, Inc. (HSIC)108— Illumina, Inc. (ILMN)109✓ Baxter International Inc. (BAX)110— Becton, Dickinson and Company (BDX)111✓ Revvity, Inc. (RVTY)112✓ Stryker Corporation (SYK)113— Tenet Healthcare Corporation (THC)114✓ Hologic, Inc. (HOLX)115✓ Zimmer Biomet Holdings, Inc. (ZBH)116✓ Owens & Minor, Inc. (ACH)117
Reciprocity shown where the peer’s own current proxy has been read — each mark is cited in the register to that peer’s filing. A dash means the peer’s current proxy was read and names no reciprocal group including Quest Diagnostics Inc.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Tenet Healthcare Corporation | 2025 | Saum Sutaria | $1,500,000 | $31,677,365 | $0 | $9,000,000 | $43,108,969 |
| 2 | Baxter International Inc. | 2025 | Andrew Hider | 499,315 | 23,133,518 | 3,185,053 | 820,125 | 29,805,182 |
| 3 | Boston Scientific Corporation | 2025 | Michael Mahoney | 1,442,603 | 13,608,056 | 3,749,980 | 4,002,001 | 23,532,050 |
| 4 | Stryker Corporation | 2025 | Kevin Lobo | 1,500,000 | 9,764,136 | 6,920,781 | 2,250,000 | 21,401,495 |
| 5 | Laboratory Corporation of America Holdings | 2025 | Adam Schechter | 1,435,000 | 11,400,463 | 2,754,582 | 2,062,095 | 18,339,913 |
| 6 | DaVita Inc. | 2025 | Javier Rodriguez | 1,500,000 | 11,442,481 | 2,699,982 | 2,089,491 | 18,210,597 |
| 7 | Becton, Dickinson and Company | 2025 | Thomas Polen | 1,395,463 | 9,991,854 | 3,311,861 | 1,852,010 | 17,129,140 |
| 8 | Zimmer Biomet Holdings, Inc. | 2025 | Ivan Tornos | 1,281,846 | 12,000,101 | 0 | 2,420,767 | 16,106,550 |
| 9 | Hologic, Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 10 | Quest Diagnostics Inc | 2025 | James Davis | 1,250,000 | 8,762,861 | 2,999,873 | 2,205,844 | 15,498,479 |
| 11 | Revvity, Inc. | 2025 | Prahlad R. Singh | 1,129,231 | 7,694,985 | 2,559,152 | 2,385,450 | 13,809,549 |
| 12 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
| 13 | Henry Schein, Inc. | 2025 | Stanley Bergman | 1,707,000 | 7,764,800 | 0 | 2,289,251 | 12,013,915 |
| 14 | Owens & Minor, Inc. | 2025 | Edward Pesicka | 1,150,000 | 9,560,140 | — | 345,000 | 11,157,809 |
| 15 | Illumina, Inc. | 2025 | Jacob Thaysen | 1,000,000 | 8,763,122 | 0 | 1,155,000 | 11,018,895 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Quest Diagnostics Inc | 113.9% | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | Semler Brossy |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Option 20 · RSU 20 | No | Semler Brossy |
| Baxter International Inc. | not disclosed | PSU 50 · RSU 25 · Option 25 | No | Aon |
| Becton, Dickinson and Company | 85% | PSU 50 · Options 25 · RSU 25 | No | Semler Brossy |
| Boston Scientific Corporation | 173% | PSU 50 · RSU 25 · Options 25 | No | Semler Brossy Consulting Group, LLC |
| DaVita Inc. | 93% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR v. S&P Health Care Services Select Industry Index | Compensia |
| Henry Schein, Inc. | 89.3% | PSU 65 · RSU 35 | No | Pearl Meyer |
| Hologic, Inc. | 109% | PSU 50 · RSU 25 · Option 25 | No | Pearl Meyer & Partners, LLC |
| Illumina, Inc. | not disclosed | not disclosed | Yes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology Index | Aon |
| Laboratory Corporation of America Holdings | 95.8% | PSU 60 · RSU 20 · Options 20 | Yes — RELATIVE TSR MODIFIER | FW Cook |
| Owens & Minor, Inc. | 20% | RSU 50 · PSU 50 | not disclosed | Frederic W. Cook & Co., Inc. (FW Cook) |
| Revvity, Inc. | 124% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| Stryker Corporation | 100% | PSU 48 · Options 34 | No | Semler Brossy |
| Tenet Healthcare Corporation | 200% | PSU 60 · RSU 40 | No | Meridian Compensation Partners, LLC |
| Zimmer Biomet Holdings, Inc. | 125.9% | RSU 50 · PSU 50 | Yes — Relative TSR | Semler Brossy |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-20 | 86,869,738 | 7,152,448 | 177,559 | 92.39% | Passed |
| 2025 | 2025-05-15 | 85,922,577 | 8,570,674 | 308,225 | 90.93% | Passed |
| 2024 | 2024-05-16 | 82,487,007 | 10,576,934 | 417,002 | 88.63% | Passed |
| 2023 | 2023-05-17 | 83,289,135 | 9,124,611 | 281,877 | 90.13% | Passed |
| 2022 | 2022-05-18 | 82,997,189 | 10,322,124 | 2,037,887 | 88.94% | Passed |
| 2021 | 2021-05-21 | 97,167,522 | 10,261,286 | 362,330 | 90.45% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-20 | 92.39%a |
| 2025 | 2025-05-15 | 90.93%b |
| 2024 | 2024-05-16 | 88.63%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 275 : 1 |
|---|---|
| CEO total compensation | $15,498,479 |
| Median employee compensation | $56,427 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Mark E. Delaney | SVP & Chief Commercial Officer | 2026-04-20 | A | 37 | $195 | $7,204 | Common | Form 4 ↗ |
| Wright L. Lassiter III | Director | 2026-04-20 | A | 6 | 195 | 1,168 | Common | Form 4 ↗ |
| Vicky B. Gregg | Director | 2026-04-20 | A | 68 | 195 | 13,239 | Common | Form 4 ↗ |
| Robert B. Carter | Director | 2026-04-20 | A | 7 | 195 | 1,363 | Common | Form 4 ↗ |
| Patrick Plewman | SVP for Diagnostic Services | 2026-04-20 | A | 49 | 195 | 9,540 | Common | Form 4 ↗ |
| Sam Samad | Executive Vice President & CFO | 2026-04-20 | A | 108 | 195 | 21,027 | Common | Form 4 ↗ |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026-04-20 | A | 39 | 195 | 7,593 | Common | Form 4 ↗ |
| Gary M. Pfeiffer | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Timothy M. Ring | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Wright L. Lassiter III | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Tracey C. Doi | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Timothy C. Wentworth | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Robert B. Carter | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Vicky B. Gregg | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Luis A. Diaz, Jr | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Timothy L. Main | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Denise M. Morrison | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| J. E. Davis | Director | 2026-06-01 | D | 10,000 | 194 | 1,941,400 | Common | Form 4 ↗ |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026-06-04 | D | 3,320 | 128 | 424,047 | Derivative, Class A Common | Form 4 ↗ |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026-06-04 | D | 8,147 | 200 | 1,629,400 | Common | Form 4 ↗ |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026-06-04 | A | 4,827 | 122 | 587,953 | Common | Form 4 ↗ |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026-06-04 | A | 3,320 | 128 | 424,047 | Common | Form 4 ↗ |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026-06-04 | D | 4,827 | 122 | 587,953 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-01 | — | 144 | — | — | 1 insider, 1 accrual row | ||
| Mark E. Delaney | SVP & Chief Commercial Officer | 2026-07-22 | A | 34 | 207 | 7,031 | Common | Form 4 ↗ |
| Sam Samad | Executive Vice President & CFO | 2026-07-22 | A | 102 | 207 | 21,094 | Common | Form 4 ↗ |
| Timothy L. Main | Director | 2026-07-22 | A | 21 | 207 | 4,343 | Common | Form 4 ↗ |
| Vicky B. Gregg | Director | 2026-07-22 | A | 72 | 207 | 14,890 | Common | Form 4 ↗ |
| Patrick Plewman | SVP for Diagnostic Services | 2026-07-22 | A | 46 | 207 | 9,513 | Common | Form 4 ↗ |
| Robert B. Carter | Director | 2026-07-22 | A | 11 | 207 | 2,275 | Common | Form 4 ↗ |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026-07-22 | A | 37 | 207 | 7,652 | Common | Form 4 ↗ |
| Wright L. Lassiter III | Director | 2026-07-22 | A | 6 | 207 | 1,241 | Common | Form 4 ↗ |
| Mark E. Delaney | SVP & Chief Commercial Officer | 2026-07-28 | D | 1,600 | 235 | 376,288 | Common | Form 4 ↗ |
| Michael Prevoznik | SVP & General Counsel | 2026-08-28 | D | 22,677 | 112 | 2,543,679 | Derivative, Class A Common | Form 4 ↗ |
| Michael Prevoznik | SVP & General Counsel | 2026-08-28 | D | 1,000 | 0 | 0 | Common | Form 4 ↗ |
| Michael Prevoznik | SVP & General Counsel | 2026-08-28 | D | 16,010 | 243 | 3,888,437 | Common, open-market sale | Form 4 ↗ |
| Michael Prevoznik | SVP & General Counsel | 2026-08-28 | A | 22,677 | 112 | 2,543,679 | Common | Form 4 ↗ |
| Michael Prevoznik | SVP & General Counsel | 2026-08-28 | D | 430 | 245 | 105,141 | Common, open-market sale | Form 4 ↗ |
| Michael Prevoznik | SVP & General Counsel | 2026-08-28 | D | 6,237 | 244 | 1,519,505 | Common, open-market sale | Form 4 ↗ |
| J. E. Davis | Director | 2026-09-01 | D | 10,000 | 243 | 2,427,200 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-01 | — | 135 | — | — | 1 insider, 1 accrual row | ||
| Patrick Plewman | SVP for Diagnostic Services | 2026-10-21 | A | 41 | 236 | 9,674 | Common | Form 4 ↗ |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026-10-21 | A | 33 | 236 | 7,786 | Common | Form 4 ↗ |
| Timothy L. Main | Director | 2026-10-21 | A | 18 | 236 | 4,247 | Common | Form 4 ↗ |
| Robert B. Carter | Director | 2026-10-21 | A | 10 | 236 | 2,359 | Common | Form 4 ↗ |
| Sam Samad | Executive Vice President & CFO | 2026-10-21 | A | 90 | 236 | 21,235 | Common | Form 4 ↗ |
| Wright L. Lassiter III | Director | 2026-10-21 | A | 6 | 236 | 1,416 | Common | Form 4 ↗ |
| Mark E. Delaney | SVP & Chief Commercial Officer | 2026-10-21 | A | 25 | 236 | 5,899 | Common | Form 4 ↗ |
| Vicky B. Gregg | Director | 2026-10-21 | A | 63 | 236 | 14,864 | Common | Form 4 ↗ |
| Gary M. Pfeiffer | Director | 2026-10-26 | D | 1,203 | 243 | 292,329 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 50 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Mark E. Delaney | SVP & Chief Commercial Officer | 2026-04-20 | A | 37 | $195 | $7,204 | Common | Form 4 ↗ |
| Wright L. Lassiter III | Director | 2026-04-20 | A | 6 | 195 | 1,168 | Common | Form 4 ↗ |
| Vicky B. Gregg | Director | 2026-04-20 | A | 68 | 195 | 13,239 | Common | Form 4 ↗ |
| Robert B. Carter | Director | 2026-04-20 | A | 7 | 195 | 1,363 | Common | Form 4 ↗ |
| Patrick Plewman | SVP for Diagnostic Services | 2026-04-20 | A | 49 | 195 | 9,540 | Common | Form 4 ↗ |
| Sam Samad | Executive Vice President & CFO | 2026-04-20 | A | 108 | 195 | 21,027 | Common | Form 4 ↗ |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026-04-20 | A | 39 | 195 | 7,593 | Common | Form 4 ↗ |
| Gary M. Pfeiffer | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Timothy M. Ring | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Wright L. Lassiter III | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Tracey C. Doi | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Timothy C. Wentworth | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Robert B. Carter | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Vicky B. Gregg | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Luis A. Diaz, Jr | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Timothy L. Main | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| Denise M. Morrison | Director | 2026-05-20 | A | 1,142 | 0 | 0 | Common | Form 4 ↗ |
| J. E. Davis | Director | 2026-06-01 | D | 10,000 | 194 | 1,941,400 | Common | Form 4 ↗ |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026-06-04 | D | 3,320 | 128 | 424,047 | Derivative, Class A Common | Form 4 ↗ |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026-06-04 | D | 8,147 | 200 | 1,629,400 | Common | Form 4 ↗ |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026-06-04 | A | 4,827 | 122 | 587,953 | Common | Form 4 ↗ |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026-06-04 | A | 3,320 | 128 | 424,047 | Common | Form 4 ↗ |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026-06-04 | D | 4,827 | 122 | 587,953 | Derivative, Class A Common | Form 4 ↗ |
| Timothy C. Wentworth | Director | 2026-07-01 | A | 144 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark E. Delaney | SVP & Chief Commercial Officer | 2026-07-22 | A | 34 | 207 | 7,031 | Common | Form 4 ↗ |
| Sam Samad | Executive Vice President & CFO | 2026-07-22 | A | 102 | 207 | 21,094 | Common | Form 4 ↗ |
| Timothy L. Main | Director | 2026-07-22 | A | 21 | 207 | 4,343 | Common | Form 4 ↗ |
| Vicky B. Gregg | Director | 2026-07-22 | A | 72 | 207 | 14,890 | Common | Form 4 ↗ |
| Patrick Plewman | SVP for Diagnostic Services | 2026-07-22 | A | 46 | 207 | 9,513 | Common | Form 4 ↗ |
| Robert B. Carter | Director | 2026-07-22 | A | 11 | 207 | 2,275 | Common | Form 4 ↗ |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026-07-22 | A | 37 | 207 | 7,652 | Common | Form 4 ↗ |
| Wright L. Lassiter III | Director | 2026-07-22 | A | 6 | 207 | 1,241 | Common | Form 4 ↗ |
| Mark E. Delaney | SVP & Chief Commercial Officer | 2026-07-28 | D | 1,600 | 235 | 376,288 | Common | Form 4 ↗ |
| Michael Prevoznik | SVP & General Counsel | 2026-08-28 | D | 22,677 | 112 | 2,543,679 | Derivative, Class A Common | Form 4 ↗ |
| Michael Prevoznik | SVP & General Counsel | 2026-08-28 | D | 1,000 | 0 | 0 | Common | Form 4 ↗ |
| Michael Prevoznik | SVP & General Counsel | 2026-08-28 | D | 16,010 | 243 | 3,888,437 | Common, open-market sale | Form 4 ↗ |
| Michael Prevoznik | SVP & General Counsel | 2026-08-28 | A | 22,677 | 112 | 2,543,679 | Common | Form 4 ↗ |
| Michael Prevoznik | SVP & General Counsel | 2026-08-28 | D | 430 | 245 | 105,141 | Common, open-market sale | Form 4 ↗ |
| Michael Prevoznik | SVP & General Counsel | 2026-08-28 | D | 6,237 | 244 | 1,519,505 | Common, open-market sale | Form 4 ↗ |
| J. E. Davis | Director | 2026-09-01 | D | 10,000 | 243 | 2,427,200 | Common | Form 4 ↗ |
| Timothy C. Wentworth | Director | 2026-10-01 | A | 135 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick Plewman | SVP for Diagnostic Services | 2026-10-21 | A | 41 | 236 | 9,674 | Common | Form 4 ↗ |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026-10-21 | A | 33 | 236 | 7,786 | Common | Form 4 ↗ |
| Timothy L. Main | Director | 2026-10-21 | A | 18 | 236 | 4,247 | Common | Form 4 ↗ |
| Robert B. Carter | Director | 2026-10-21 | A | 10 | 236 | 2,359 | Common | Form 4 ↗ |
| Sam Samad | Executive Vice President & CFO | 2026-10-21 | A | 90 | 236 | 21,235 | Common | Form 4 ↗ |
| Wright L. Lassiter III | Director | 2026-10-21 | A | 6 | 236 | 1,416 | Common | Form 4 ↗ |
| Mark E. Delaney | SVP & Chief Commercial Officer | 2026-10-21 | A | 25 | 236 | 5,899 | Common | Form 4 ↗ |
| Vicky B. Gregg | Director | 2026-10-21 | A | 63 | 236 | 14,864 | Common | Form 4 ↗ |
| Gary M. Pfeiffer | Director | 2026-10-26 | D | 1,203 | 243 | 292,329 | Common | Form 4 ↗ |
Sources (117 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, James Davis. DEF 14A, filed 2026-04-06. Section “2025 Summary Compensation Table” · page 46. As printed: 15,498,479. View filing ↗
- Section 01, Sam Samad. DEF 14A, filed 2026-04-06. Section “2025 Summary Compensation Table” · page 46. As printed: 4,427,141. View filing ↗
- Section 01, Catherine Doherty. DEF 14A, filed 2026-04-06. Section “2025 Summary Compensation Table” · page 46. As printed: 3,562,946. View filing ↗
- Section 01, Karthik Kuppusamy. DEF 14A, filed 2026-04-06. Section “2025 Summary Compensation Table” · page 46. As printed: 2,579,823. View filing ↗
- Section 01, Michael Prevoznik. DEF 14A, filed 2026-04-06. Section “2025 Summary Compensation Table” · page 46. As printed: 2,563,593. View filing ↗
- Section 03, Catherine Doherty RSU. DEF 14A, filed 2026-04-06. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Prevoznik RSU. DEF 14A, filed 2026-04-06. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, James Davis RSU. DEF 14A, filed 2026-04-06. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Karthik Kuppusamy PSU. DEF 14A, filed 2026-04-06. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Prevoznik PSU. DEF 14A, filed 2026-04-06. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Sam Samad RSU. DEF 14A, filed 2026-04-06. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Karthik Kuppusamy RSU. DEF 14A, filed 2026-04-06. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, James Davis PSU. DEF 14A, filed 2026-04-06. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Catherine Doherty PSU. DEF 14A, filed 2026-04-06. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Sam Samad OPTION. DEF 14A, filed 2026-04-06. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Karthik Kuppusamy OPTION. DEF 14A, filed 2026-04-06. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Catherine Doherty OPTION. DEF 14A, filed 2026-04-06. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Sam Samad PSU. DEF 14A, filed 2026-04-06. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Prevoznik OPTION. DEF 14A, filed 2026-04-06. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, James Davis OPTION. DEF 14A, filed 2026-04-06. Section “2025 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-06. Section “CEO Pay Ratio”. As printed: 275 : 1. View filing ↗
- Section 08, Timothy M. Ring. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 379,917. View filing ↗
- Section 08, Gary M. Pfeiffer. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 349,917. View filing ↗
- Section 08, Vicky B. Gregg. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 344,917. View filing ↗
- Section 08, Denise M. Morrison. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 344,917. View filing ↗
- Section 08, Timothy L. Main. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 339,917. View filing ↗
- Section 08, Luis A. Diaz, Jr. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 324,917. View filing ↗
- Section 08, Wright L. Lassiter III. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 324,917. View filing ↗
- Section 08, Tracey C. Doi. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 324,917. View filing ↗
- Section 08, Robert B. Carter. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 324,917. View filing ↗
- Section 08, Timothy C. Wentworth. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, James E. Davis. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Mark E. Delaney 2026-04-20. Form 4, filed 2026-04-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wright L. Lassiter III 2026-04-20. Form 4, filed 2026-04-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vicky B. Gregg 2026-04-20. Form 4, filed 2026-04-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert B. Carter 2026-04-20. Form 4, filed 2026-04-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Plewman 2026-04-20. Form 4, filed 2026-04-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sam Samad 2026-04-20. Form 4, filed 2026-04-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karthik Kuppusamy 2026-04-20. Form 4, filed 2026-04-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gary M. Pfeiffer 2026-05-20. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy M. Ring 2026-05-20. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wright L. Lassiter III 2026-05-20. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tracey C. Doi 2026-05-20. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy C. Wentworth 2026-05-20. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert B. Carter 2026-05-20. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vicky B. Gregg 2026-05-20. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Luis A. Diaz, Jr 2026-05-20. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy L. Main 2026-05-20. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Denise M. Morrison 2026-05-20. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, J. E. Davis 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karthik Kuppusamy 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karthik Kuppusamy 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karthik Kuppusamy 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karthik Kuppusamy 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karthik Kuppusamy 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy C. Wentworth 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark E. Delaney 2026-07-22. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sam Samad 2026-07-22. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy L. Main 2026-07-22. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vicky B. Gregg 2026-07-22. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Plewman 2026-07-22. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert B. Carter 2026-07-22. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karthik Kuppusamy 2026-07-22. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wright L. Lassiter III 2026-07-22. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark E. Delaney 2026-07-28. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Prevoznik 2026-08-28. Form 4, filed 2026-08-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Prevoznik 2026-08-28. Form 4, filed 2026-08-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Prevoznik 2026-08-28. Form 4, filed 2026-08-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Prevoznik 2026-08-28. Form 4, filed 2026-08-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Prevoznik 2026-08-28. Form 4, filed 2026-08-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Prevoznik 2026-08-28. Form 4, filed 2026-08-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, J. E. Davis 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy C. Wentworth 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Plewman 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karthik Kuppusamy 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy L. Main 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert B. Carter 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sam Samad 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wright L. Lassiter III 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark E. Delaney 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vicky B. Gregg 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gary M. Pfeiffer 2026-10-26. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-21. Item 5.07 · say-on-pay result. As reported: 92.39% (votes for as printed: 86,869,738). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-22. Item 5.07 · say-on-pay result. As reported: 90.93% (votes for as printed: 85,922,577). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-21. Item 5.07 · say-on-pay result. As reported: 88.63% (votes for as printed: 82,487,007). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 1,170,000 + equity 1,889,253 + all other 0 = 3,059,253, summed across the director compensation table rows.
- Tenet Healthcare Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Tenet Healthcare Corporation's own proxy. As printed: 43,108,969. View filing ↗
- Baxter International Inc., Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Baxter International Inc.'s own proxy. As printed: 29,805,182. View filing ↗
- Boston Scientific Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-18. CEO total compensation as printed in Boston Scientific Corporation's own proxy. As printed: 23,532,050. View filing ↗
- Stryker Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Stryker Corporation's own proxy. As printed: 21,401,495. View filing ↗
- Laboratory Corporation of America Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Laboratory Corporation of America Holdings's own proxy. As printed: 18,339,913. View filing ↗
- DaVita Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in DaVita Inc.'s own proxy. As printed: 18,210,597. View filing ↗
- Becton, Dickinson and Company, Section 10b CEO total. DEF 14A, filed 2025-12-18. CEO total compensation as printed in Becton, Dickinson and Company's own proxy. As printed: 17,129,140. View filing ↗
- Zimmer Biomet Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Zimmer Biomet Holdings, Inc.'s own proxy. As printed: 16,106,550. View filing ↗
- Hologic, Inc., Section 10b CEO total. DEF 14A, filed 2025-01-16. CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. View filing ↗
- Quest Diagnostics Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Quest Diagnostics Inc's own proxy. As printed: 15,498,479. View filing ↗
- Revvity, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Revvity, Inc.'s own proxy. As printed: 13,809,549. View filing ↗
- Agilent Technologies, Inc., Section 10b CEO total. DEF 14A, filed 2026-02-06. CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. View filing ↗
- Henry Schein, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Henry Schein, Inc.'s own proxy. As printed: 12,013,915. View filing ↗
- Owens & Minor, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Owens & Minor, Inc.'s own proxy. As printed: 11,157,809. View filing ↗
- Illumina, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. View filing ↗
- Section 10a, Agilent Technologies, Inc. reciprocity. DEF 14A. Agilent Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include Quest Diagnostics Inc. View filing ↗
- Section 10a, Laboratory Corporation of America Holdings reciprocity. DEF 14A. Laboratory Corporation of America Holdings names Quest Diagnostics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Boston Scientific Corporation reciprocity. DEF 14A. Boston Scientific Corporation names Quest Diagnostics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, DaVita Inc. reciprocity. DEF 14A. DaVita Inc. names Quest Diagnostics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Henry Schein, Inc. reciprocity. DEF 14A. Henry Schein, Inc. names Quest Diagnostics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Illumina, Inc. reciprocity. DEF 14A. Illumina, Inc.'s most recent proxy was read; its disclosed peer group does not include Quest Diagnostics Inc. View filing ↗
- Section 10a, Baxter International Inc. reciprocity. DEF 14A. Baxter International Inc. names Quest Diagnostics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Becton, Dickinson and Company reciprocity. DEF 14A. Becton, Dickinson and Company's most recent proxy was read; its disclosed peer group does not include Quest Diagnostics Inc. View filing ↗
- Section 10a, Revvity, Inc. reciprocity. DEF 14A. Revvity, Inc. names Quest Diagnostics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Stryker Corporation reciprocity. DEF 14A. Stryker Corporation names Quest Diagnostics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Tenet Healthcare Corporation reciprocity. DEF 14A. Tenet Healthcare Corporation's most recent proxy was read; its disclosed peer group does not include Quest Diagnostics Inc. View filing ↗
- Section 10a, Hologic, Inc. reciprocity. DEF 14A. Hologic, Inc. names Quest Diagnostics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Zimmer Biomet Holdings, Inc. reciprocity. DEF 14A. Zimmer Biomet Holdings, Inc. names Quest Diagnostics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Owens & Minor, Inc. reciprocity. DEF 14A. Owens & Minor, Inc. names Quest Diagnostics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗